Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aldeyra Therapeutics, Inc. (ALDX : NSDQ)

• Company Description    Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $4.69 Daily Weekly Monthly 20 Day Moving Average: 625,085 shares Shares Outstanding: 60.16 (millions) Market Capitalization: $282.16 (millions) Beta: 0.79 52 Week High: $7.20 52 Week Low: $1.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.99% -15.27% 12 Week -12.99% -16.59% Year To Date -6.01% -17.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 HARTWELL AVENUE SUITE 320 - LEXINGTON,MA 02421 USA ph: 781-761-4904 fax: 781-270-0630 investorrelations@aldeyra.com http://www.aldeyra.com

• General Corporate Information    Officers Todd C. Brady - President; Chief Executive Officer and Director Richard H. Douglas - Chairman Ben Bronstein - Director Martin J. Joyce - Director Nancy Miller-Rich - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 01438T106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/27/26 Share - Related Items Shares Outstanding: 60.16 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $282.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.00% vs. Previous Quarter: 18.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -72.25 06/30/25 - -73.63 03/31/25 - -72.58 ROA 09/30/25 - -47.92 06/30/25 - -50.61 03/31/25 - -52.32 Current Ratio 09/30/25 - 2.72 06/30/25 - 2.86 03/31/25 - 6.49 Quick Ratio 09/30/25 - 2.72 06/30/25 - 2.86 03/31/25 - 6.49 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 0.82 06/30/25 - 0.92 03/31/25 - 1.06 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.24 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 19.19

Powered by Zacks Investment Research ©